Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.31 |
| ▸ | CCKAR | P32238 | 3/20 | 0.31 |
| ▸ | CCKBR | P32239 | 3/20 | 0.31 |
| ▸ | SLC33A1 | O00400 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964400 | 0.89 | DPP4 (0.39) | DPP4KCNH2DPP7XDHPARP1 | |
| SCHEMBL3969106 | 0.89 | DPP4 (0.38) | DPP4KCNH2DPP7RBP4AGTR1 | |
| SCHEMBL3963063 | 0.83 | PARP1 (0.33) | DPP4KCNH2DPP7XDHPARP1 | |
| SCHEMBL3965561 | 0.81 | BRD4 (0.32) | DPP4KCNH2DPP7 | |
| SCHEMBL3965271 | 0.80 | DPP4 (0.31) | DPP4KCNH2DPP7 | |
| SCHEMBL3382566 | 0.80 | TERT (0.34) | — | |
| SCHEMBL3966059 | 0.76 | PARP1 (0.33) | PARP1 | |
| SCHEMBL3965157 | 0.73 | — | — | |
| SCHEMBL3963066 | 0.71 | AGTR1 (0.35) | DPP4KCNH2DPP7XDHAGTR1 | |
| SCHEMBL3967467 | 0.70 | XDH (0.35) | DPP4KCNH2DPP7XDHPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRM1 | DPP4 2760/4885KCNH2 569/4885DPP7 3977/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | DPP4 2274/4885KCNH2 618/4885DPP7 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.